NDABUCCAL, SUBLINGUALFILM
Approved
Apr 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
IGALMI (dexmedetomidine) by BioXcel Therapeutics is adrenergic alpha2-agonists [moa]. Approved for sedation, delirium, icu sedation and 3 more indications. First approved in 2022.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IGALMI (dexmedetomidine) is a central alpha-2 adrenergic agonist delivered as a buccal/sublingual film for rapid sedation and anxiety management. It is indicated across ICU sedation, procedural sedation, delirium, and emerging neuropsychiatric conditions including PTSD, alcohol withdrawal, and Alzheimer's disease. The drug works by activating alpha-2 adrenergic receptors in the CNS to produce sedative and anxiolytic effects with minimal respiratory depression.
$65KPart D
Peak16.7 years to LOEEarly-stage commercial trajectory with minimal Part D penetration suggests significant growth opportunity; small current claims volume indicates nascent adoption requiring field expansion.
Mechanism of Action
Adrenergic alpha2-Agonists
Pharmacologic Class:
Central alpha-2 Adrenergic Agonist
Indications (6)
Worked on IGALMI at BioXcel Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.